FDA Issues New Warning Regarding Compounded Ketamine

On October 10, 2023, the U.S. Food and Drug Administration (FDA) issued a public warning regarding the potential health risks associated with compounded ketamine products. This warning follows a February 16, 2022 alert regarding the potential risks associated with compounded ketamine nasal spray. The October 10 warning notes that even though there has been widespread marketing for ketamine to treat psychiatric disorders (e.g., depression, anxiety, post-traumatic stress disorder (PTSD), and…
By: Foley & Lardner LLP
Previous Story

Manufacturing Giant Regal Rexnord Files Notice of Data Breach Impacting an Unknown Number of People

Next Story

Tri Counties Bank Announces Data Breach Impacting Sensitive Employee and Customer Information